Roth Capital initiated coverage on Biofrontera with a new price target
$BFRI
Biotechnology: Pharmaceutical Preparations
Health Care
Roth Capital initiated coverage of Biofrontera with a rating of Buy and set a new price target of $20.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/15/2021 | $11.00 | Buy | Benchmark |
| 11/24/2021 | $20.00 | Buy | Roth Capital |
Fourth quarter results represent highest quarterly revenue in Company's historyQ4 year-over-year growth of 35% to 39% driven by sales execution of Ameluz®Full year 2025 revenues also expected to show double-digit growth of 11% to 13% WOBURN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a leader in photodynamic therapy (PDT) development and commercialization, today announced preliminary unaudited revenue results for the fourth quarter ended December 31, 2025. Fourth quarter revenues are expected to be between $17.0 million and $17.5 million, representing the highest quarterly revenue in the Company's history. For the full year 2
Database locks for studies on actinic keratosis (AK) and acne vulgaris achieved on January 5, 2026Data generated will support key regulatory milestones for Ameluz PDT in both indicationsAK and acne are the two most commonly diagnosed skin disorders in the US1 WOBURN, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the successful database lock of two clinical studies evaluating Ameluz® PDT, marking an important milestone ahead of several anticipated data and regulatory events in 2026. The databases for th
• Ameluz® and RhodoLED® New Drug Application (NDA) and Investigational New Drug Application (IND) have successfully been transferred to Biofrontera Inc.• Assignment to Biofrontera Inc. of 11 granted US patents, 10 pending US patent applications and various trademarks associated with Ameluz® and the RhodoLED® Lamp Series has been applied for registration with the relevant authorities, including the US Patent Office (USPTO)• In addition, 19 international patent applications and/or registered designs for RhodoLED® lamps outside of the US were acquired and registration of the transfer has been initiated WOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofron
8-K - Biofrontera Inc. (0001858685) (Filer)
8-K - Biofrontera Inc. (0001858685) (Filer)
EFFECT - Biofrontera Inc. (0001858685) (Filer)
Benchmark initiated coverage of Biofrontera with a rating of Buy and set a new price target of $11.00
Roth Capital initiated coverage of Biofrontera with a rating of Buy and set a new price target of $20.00
3 - Biofrontera Inc. (0001858685) (Issuer)
3 - Biofrontera Inc. (0001858685) (Issuer)
3 - Biofrontera Inc. (0001858685) (Issuer)
Woburn, MA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced the appointment of George Jones as Chief Commercial Officer (CCO), starting August 25, 2025. In this role, Mr. Jones will oversee the Company's commercial functions, including sales, marketing, and market access. He will report directly to CEO Dr. Hermann Luebbert. This strengthening of the Company's management follows the recent announcement of an agreement to acquire all rights and assets related to Ameluz® and RhodoLED® for the US market, including the FDA approval and al
WOBURN, MA / ACCESSWIRE / August 29, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announced today the appointment of Samantha (Sam) Widdicombe to the newly created position of Senior Director, Strategic Accounts and Communications. Biofrontera created this position in response to the growing demand and opportunity for specialized sales and marketing approaches resulting from an evolving landscape of medical practices consolidating into larger integrated organizations.Reporting to Mark Baldyga, Vice President of Sales and Marketing, Ms. Widdicombe joins Biofrontera with over
WOBURN, MA / ACCESSWIRE / July 12, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces the appointment of Heikki Lanckriet, Ph.D. to its Board of Directors. Dr. Lanckriet brings to Biofrontera more than 20 years of commercial and scientific experience in the life sciences industry, along with proven success in developing high-growth technology companies.Dr. Lanckriet was nominated to Biofrontera Inc.'s Board of Directors by Biofrontera AG under the terms of the April 2023 settlement agreement between the two companies previously disclosed in the Company's Current Report o
Fourth quarter results represent highest quarterly revenue in Company's historyQ4 year-over-year growth of 35% to 39% driven by sales execution of Ameluz®Full year 2025 revenues also expected to show double-digit growth of 11% to 13% WOBURN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a leader in photodynamic therapy (PDT) development and commercialization, today announced preliminary unaudited revenue results for the fourth quarter ended December 31, 2025. Fourth quarter revenues are expected to be between $17.0 million and $17.5 million, representing the highest quarterly revenue in the Company's history. For the full year 2
Conference call will be held today, Thursday, November 13 at 10:00 am ET Woburn, MA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three and nine months ended September 30, 2025 and provided a business update. Financial highlights Revenues for the first nine months of 2025 were stable with $24.6 million compared to $24.8 million for the same period in 2024The 2025 result was achieved without the buy-in effects from a price increaseIn 3Q25 revenues were $7.0 million, lagging behind the
WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and nine months ended September 30, 2025 after the close of the U.S. financial markets on Wednesday, November 12, 2025. The company will host a conference call on Thursday, November 13 at 10:00am Eastern Time to discuss those results, provide a business update and answer questions. Conference Call and Webcast Information Event:Biofrontera Inc. Third Quarter 2025 Financial Results and Business Update Conference CallDate:Thursday,
SC 13G/A - Biofrontera Inc. (0001858685) (Subject)
SC 13G/A - Biofrontera Inc. (0001858685) (Subject)
SC 13G/A - Biofrontera Inc. (0001858685) (Subject)